Christopher Cann, MD
Hematology & Oncology · Philadelphia, PANPI 1124552898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,409 of the $5,817 with a category attached, or 75.8%. Taiho Oncology, Inc. accounts for 70.6% of it on its own, with 10 other manufacturers making up the rest.
Across 25 payments — averaging $232.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Taiho Oncology, Inc.$4K
- Regeneron$659
- AstraZeneca$459
- Gilead$209
- Eisai Inc.$132
- Intera Oncology, Inc$107
- plus $142 from 5 others
Across 1 payment — averaging $83,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$84K
What the payments were for
- Consulting fees$4,40976%
- Food & beverage$1,40824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Taiho Oncology, Inc. | 4 | $4,109 |
| Regeneron | 1 | $659 |
| AstraZeneca | 8 | $459 |
| Gilead | 3 | $209 |
| Eisai Inc. | 2 | $132 |
| Intera Oncology, Inc | 1 | $107 |
| Tempus AI, Inc | 2 | $48 |
| Astellas Pharma US Inc | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,817 in reported general payments places this provider in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $8,565 |
| Prochlorperazine Maleate | 43 | $415 |
| Potassium Chloride | 12 | $255 |
| Ondansetron Hcl | 33 | $204 |
| Gabapentin | 24 | $159 |
| Oxycodone Hcl | 15 | $143 |
| Pantoprazole Sodium | 12 | $119 |
| Ondansetron OdtOndansetron | 14 | $114 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.